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Abstract
Treatment options for hepatocellular carcinoma have evolved over recent years. Interventional radiologists and
surgeons can offer curative treatments for early stage tumours, and locoregional therapies can be provided
resulting in longer survival times. Early diagnosis with screening ultrasound is the key. CT and MRI are used to
characterize lesions and determine the extent of tumour burden. Imaging techniques are discussed in this article as
the correct imaging protocols are essential to optimise successful detection and characterisation. After treatment it
is important to establish regular imaging follow up with CT or MRI as local residual disease can be easily treated,
and recurrence elsewhere in the liver is common.
Background
Hepatocellular carcinoma (HCC) is the most common
liver cancer and the fifth most common cancer world-
wide. It results in between 250,000 and 1 million deaths
globally per annum [1]. The number of deaths per year
in HCC is close to that of the incidence throughout the
world, which emphasizes the high case fatality rate of
this aggressive cancer [1].
80% of HCC cases are associated with chronic hepatitis
B and C virus infections [2]. Alcoholic liver disease is a
risk factor in younger age groups, and the combination
of alcoholic liver disease and viral hepatitis substantially
increases the risk for the development of cirrhosis and
HCC. The obesity epidemic has resulted in a growing
population of patients with non-alcoholic fatty liver dis-
ease, cirrhosis and HCC [3].
In the United States, HCC, with its link to the hepa-
titis C epidemic, represents the fastest growing cause of
cancer mortality overall and the second fastest growing
cause of cancer deaths among women [4].
Surveillance
The AASLD (American Association for the Study of
Liver Diseases) recommends screening for the following
high-risk groups: Asian male hepatitis B carriers over
age 40, Asian female hepatitis B carriers over age 50, hepa-
titis B carriers with a family history of HCC, Africans and
African Americans with hepatitis B, cirrhotic hepatitis B
carriers, individuals with hepatitis C cirrhosis, individuals
with stage 4 primary biliary cirrhosis, individuals with gen-
etic hemochromatosis and cirrhosis, individuals with alpha
1-antitypsin deficiency and cirrhosis, individuals with
cirrhosis from other etiologies [5].
We scan patients with cirrhosis from any etiology
every 6 months with ultrasound [5, 6]. Ultrasonography
remains the primary imaging modality of choice for
HCC surveillance. It is more cost-effective than CT and
MRI, and more widely available. A meta-analysis reported
a sensitivity of 94% in detecting lesions and a specificity
of >90% [7], although the figures were less favourable for
lesions measuring less than 2 cm. The sensitivity for early
HCC is 63%. Although our liver clinic routinely uses
alpha-fetoprotein as an adjunct to imaging screening, it is
acknowledged that it is neither sensitive nor specific for
early diagnosis of HCC [8].
Once a nodule is detected, further follow-up depends
on the size of the lesion(s), with both the American Asso-
ciation of the Society of Liver Diseases (AASLD) and the
European Association for the Study of the Liver, European
Organisation for Research and Treatment of Cancer
(EASL–EORTC) using a threshold for further manage-
ment of 1 cm. For nodules measuring less than 1 cm, the
patient returns for a repeat ultrasound at 3 or 4 months.
For nodules greater than 1 cm, the patient undergoes a
dynamic contrast enhanced computed tomography (CT)
or magnetic resonance imaging (MRI). The diagnosis of
HCC is then determined by imaging characteristics.
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CT or MRI
Unlike most other cancers, HCC can be diagnosed on im-
aging studies only without tissue sampling confirmation.
Currently, all major consensus groups support the diagno-
sis of HCC with contrast-enhanced multiphasic CT, or
with MRI using an extracellular contrast agent [5, 6].
Studies have shown a similar or slightly better diagnostic
performance of dynamic MR imaging compared with
multiphasic CT [9, 10] although the difference in sensi-
tivities is small [11–13].
The decision to perform one over the other may depend
on institutional preferences, individual patient needs, and
availability. Advantages of CT over MRI include lower
cost, increased availability, and faster scan times. Faster
scan times in particular can be an advantage in the con-
text of a cirrhotic population with multiple morbidities
and difficulty in cooperating with the breath hold require-
ments of MRI. Advantages of MRI include the capacity to
evaluate a greater variety of tissue properties including fat
content, restriction of diffusion, or T2-weighted increased
signal, all of which may help in lesion detection and
characterization. Lack of ionizing radiation may also be a
consideration in younger patients.
Ultrasound technique
We use a standard diagnostic 3–5 Mhz linear curved
array probe to evaluate the liver. Subcostal real time
imaging is performed of the left lobe, followed by inter-
costal and subcostal views of the right lobe. Both trans-
verse and longitudinal projections are performed. Ask
the patient to adopt a left lateral decubitus position for
visualization of the right lobe after initially imaging in
the supine position.
Initially information on the echogenicity and coarseness
of the liver echotexture is assessed, as well as smoothness
or nodularity of the liver surface. Then we look for focal
lesions. Comparison with prior studies is essential to
assess for stability or change in small hypoechoic or
hyperechoic nodules. Once a new nodule or a change
in a nodule is identified the patient goes on to CT or
MRI, often on the same day.
We look at the hepatic vasculature. Although we do
not do a full Doppler evaluation of the liver, we always
look at the portal vein for direction of flow with both
colour and spectral techniques and for any filling defects
suggestive of tumor or bland thrombus.
An interval increase in the degree of splenomegaly
can indicate a worsening of portal hypertension, so we
measure the spleen as a final component of the study
(Table 1).
MRI technique
We perform MRI of the liver at 1.5-T field strength, al-
though a 3.0-T field strength can also be used [14]. A
phased-array coil is routinely employed. Our protocol
for imaging the cirrhotic liver includes T1-weighted
gradient-recalled echo (GRE) in-phase and opposed-
phase sequences, a moderately T2-weighted FSE se-
quence with an echo time of 80–90 msec, diffusion
weighted imaging (DWI) and multiphase T1-weighted
dynamic gadolinium-enhanced sequences.
A heavily T2-weighted sequence (echo time, ≥120 msec)
can help to distinguish between cystic and solid lesions
and a fast sequence, such as single-shot FSE (or half-
Fourier acquisition turbo spin-echo—half-Fourier rapid
acquisition with relaxation enhancement), is used for
this purpose.
The sequences used can vary according to vendor
and personal preferences. To improve image quality,
sequences should be performed during suspended res-
piration or should be respiratory averaged (some T2-
weighted sequences). Suspending respiration at end
expiration produces more consistent breath holding
compared with end inspiration but is more difficult for
patients [15]. GRE sequences are widely used for T1-
weighted imaging. Using a dual gradient-echo sequence
that allows simultaneous acquisition of the earliest
opposed-phase and in-phase images minimizes misreg-
istration and improves the characterization of focal le-
sions and diffuse liver disease [16]. The acquisition of
the earliest opposed-phase echo (2.2 msec at 1.5-T and
1.15 msec at 3-T imaging) followed by the subsequent
Table 1 Summary of imaging techniques for ultrasound, MRI and CT
Ultrasound liver MRI liver CT liver
3–5 MHz Curvilinear Probe
Transverse and longitudinal imaging,
to include supine and left lateral
decubitus positions
Doppler evaluation of the portal vein
Spleen measurement
Sequences
Cor T2-w Single Shot Fast Spin
Echo +/−Fat Saturation (FS)
Ax T2-w Fast Spin Echo FS
Ax Diffusion Weighted Imaging
Ax dual gradient echo
Ax 3D Spoiled Gradient Echo FS pre and post dynamic contrast
enhancement (and coronal reconstruction in venous phase)
Ax 2D Spoiled Gradient Echo FS




IV Contrast: Iohexol 100 mL
Bolus tracking for arterial phase (average 30 s)
Venous phase 65 s
Delayed phase 240 s
Single breath for each phase
Injection rate min 4 ml/s
Slice thickness 3 mm no overlap
Coronal reconstructions in venous phases
provided.
Subtraction imaging optional
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in-phase echo enables the distinction between signal in-
tensity loss caused by the presence of lipid seen on
opposed-phase images and signal intensity loss due to
susceptibility artifact from hepatic iron deposition,
which is exaggerated on the longer of the two echoes
(usually in phase).
Three-dimensional gadolinium-enhanced GRE sequences
are preferred to two-dimensional GRE sequences because
of the thinner sections obtained, which improve lesion
detection and permit multiplanar image reconstructions
for presurgical planning [17]. Section thickness should
not exceed 4 mm for three-dimensional sequences and
6 mm for two-dimensional sequences. Contrast agent
bolus timing is strongly recommended, based on our
experience and review of the literature [18], to ensure
the consistent capturing of the arterial-dominant phase;
fixed delay is not a reliable method in this patient popu-
lation. Options include use of a test bolus and various
automated detection methods [19]. Hypervascular HCC
is most conspicuous in the late arterial phase and can be
missed if the arterial-dominant phase images are ac-
quired early [20]. A timing bolus is not essential if rapid
multiphase arterial imaging is performed. To improve
lesion characterization—for example, to detect washout or
delayed contrast material retention of hemangioma and
cholangiocarcinoma—multiphase dynamic gadolinium-
enhanced imaging should include three contrast-
enhanced phases or more. We routinely acquire four
sets of images after gadolinium-based contrast material
injection in the arterial-dominant (automated timing,
usually 20–35 s), venous (60–90 s), interstitial (120–
150 s), and delayed (5 min) phases of hepatic enhance-
ment. The highest spatial resolution should be used with-
out compromising signal intensity, taking into account
patients’ breath-holding capacity. Parallel imaging tech-
niques can be applied to improve spatial resolution and/or
reduce acquisition time. However, these techniques should
be implemented with care, because they can result in
image artifacts and reduced lesion conspicuity [21].
We find ourselves frequently dependent on subtrac-
tion imaging because of the intrinsic high signal dem-
onstrated by nodules in the cirrhotic liver, including
regenerative, dysplastic and malignant nodules. Intrinsic
high signal can also be demonstrated in successfully
treated HCC [22]. Unenhanced images can be subtracted
from arterial-phase gadolinium-enhanced images to
assess for arterial enhancement in nodules [23]. Sub-
traction can be performed if the unenhanced and
gadolinium-enhanced imaging sequences are identical,
if the imager is not retuned between acquisitions, and if
there are no image rescaling issues. Acquiring the
unenhanced and gadolinium-enhanced images in a sin-
gle series rather than in separate series minimizes these
differences and is possible with most systems. Patients
should be instructed to hold their breath in a similar
fashion during all sequences to minimize misregistra-
tion artifacts, which appear as a bright line at the edge
of organs owing to incomplete overlap. At this point
the ability of the MR radiographer or technician to
coach the patient is crucial. Consistent breath holds are
important in many MR sequences because of the
lengths of the scans, but for subtraction imaging it is
impossible to overemphasise the absolute requirement
for good breath holds. If the patient, despite careful
coaching, is unable to hold his/her breath, then CT,
despite the change in modality, may be the better form
of imaging.
Diffusion weighted imaging increases the detection
rate of HCC, particularly for small tumours [24–26]. B-
values typically used include one in the low range (0–
50 s/mm2) and one in the intermediate-to-high range
(400–800 s/mm2). We find that the DWI sequence
frequently helps us to lean in favour or against small
arterial enhancing lesions with equivocal washout as
HCC, as well as assisting us in bringing our attention
to small lesions which are inconspicuous on contrast-
enhanced sequences [27]. Tumors can be obscured on
DWI because of the increased DWI signal in fibrotic
liver parenchyma and subsequent decreased lesion to
liver contrast [28]. In addition, DWI signal may be seen
with other hepatic malignancies, such as metastases
and intrahepatic cholangiocarcinomas [28–30].
Both extracellular and hepatobiliary agents can be
used for imaging of the liver. We favour the use of the
more expensive hepatobiliary agents only in specific
cases where key decisions are to be made with regard
to transplant or locoregional treatment. Indeed, hepato-
biliary agents can present radiologists with greater diag-
nostic conundrums in contrast to more clarity.
Extracellular gadolinium-based contrast agents (for
example, gadopentetate dimeglumine (Gd-DTPA), Mag-
nevist®, Bayer HealthCare), distribute from the vascular
space into the interstitial compartment. The standard
dose is 0.1 mmol/kg typically injected intravenously at a
rate of 2 mL/s followed by a normal saline “flush” of 20
to 50 mL.
Hepatobiliary agents distribute into the interstitial
space, but, importantly for hepatic imaging, are also
taken up by hepatocytes with subsequent biliary excre-
tion. Multihance, Bracco Diagnostics, Princeton, NJ,
USA) was the first to be approved. Approximately 95%
of this agent is excreted by the kidney, but 3 to 5% is
taken up by the normal hepatocytes and excreted into
the biliary tract. Gadoxetate Disodium (U.S: Eovist,
Europe: Primovist, Bayer Healthcare Pharmaceuticals,
Wayne, NJ, USA) has approximately 50:50 excretion
between renal (glomerular filtration) and hepatocyte
uptake/biliary excretion. This can therefore be used for
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the early dynamic imaging phase in the liver, as above,
followed by a 20 min T1-weighted imaging phase
where the liver is of higher signal intensity and non-
hepatocyte containing masses will be of low signal in-
tensity. Hepatocyte-specific contrast agents have been
shown in many studies to increase lesion sensitivity for
HCC by capitalizing on evidence that poorly differenti-
ated HCCs do not contain functioning hepatocytes and
bile ducts, and therefore demonstrate hypointense signal
relative to the surrounding liver parenchyma [30, 31].
Combining contrast-enhanced MRI features and hepato-
biliary phase imaging has demonstrated sensitivities and
specificities of greater than 90% [31].
Potential pitfalls that apply specifically to Eovist/Primo-
vist include transient marked motion on arterial phase im-
ages, inability to assess washout after the portal venous
phase due to early parenchymal enhancement, difficulty
identifying “capsule appearance” due to hepatic parenchy-
mal enhancement, and difficulty identifying venous tumor
invasion due to more rapid venous clearance and de-
creased vein to liver contrast [32, 33].
The use of hepatobiliary agents for the diagnosis of
HCC is in transition. Some major HCC imaging guide-
lines do not mention this class contrast agents [5, 6, 34],
while other societies or organizations recommend their
use [35]. It remains unclear whether hepatobiliary phase
contrast hypoenhancement [32] will be more widely
incorporated in comparison with conventional extra-
cellular contrast agent imaging characteristics for the
diagnosis of HCC (Table 1).
CT technique
Multidetector CT (MDCT) allows fast, high-quality,
thin-section imaging and permits 3D reconstruction
with better spatial resolution than that of MRI. Fast in-
jection rates (4–8 ml/s) provide more reliable enhance-
ment during the hepatic arterial phase and increase the
sensitivity of CT to liver lesions. Studies have demon-
strated hypervascular components in 81–89% of HCCs
[36]. For patients with contraindications to MRI CT
serves as an adequate alternative.
CT imaging technique is based on the same principles
as dynamic contrast MRI, using arterial enhancement,
delayed washout, and a delayed enhancing pseudocap-
sule as the pillars of diagnosis. The precontrast images
serve as a baseline to gauge subsequent enhancement.
Following the injection of 100 ml of Omnipaque 350
(Iohexol) we use a bolus tracking system (threshold at-
tenuation in the aorta 150 HU) to initiate arterial phase
breathhold imaging through the liver. Subsequent series
of images are taken at 65 s and 240 s to provide venous
and delayed phase imaging Subtraction images (postcon-
trast minus precontrast) may be helpful for detection of
enhancement and evaluation of its degree [37] (Table 1).
Diagnosis of HCC and report writing
The hallmark feature of HCC on both CT and MRI is
late arterial enhancement with washout relative to the
liver parenchyma during the venous or delayed phases
(3–5 min post injection) (Fig. 1). This pattern of enhance-
ment has been shown to demonstrate high specificity and
positive predictive value [38–40] making it the noninva-
sive standard for HCC diagnosis [5, 6, 35, 41–44].
In addition to the enhancement pattern, additional fea-
tures of HCC have been described which are also specific
for HCC including capsular enhancement [30, 45, 46].
Capsular enhancement (Fig. 2) is defined as a persistent
peripheral enhancing rim seen on venous and delayed
phases.
More specific to MRI, a diagnosis of HCC is often at-
tributed to a lesion showing only arterial enhancement
or only washout and pseudocapsule formation, if the
lesion also demonstrates increased signal intensity on
T2-weighted mages [47, 48] or if the lesion restricts
Fig. 1 54 year old male with hepatitis C cirrhosis. CT shows an
arterial enhancing nodule a with washout of contrast in the delayed
phase b consistent with hepatocellular carcinoma
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diffusion [25, 27, 49], although some caution should be
applied to both of these adjuncts as they can result in
false positive interpretations [50] (Table 2).
Intracellular lipid detected within a nodule on dual-echo
in and opposed phase T1-weighted MRI is an additional
finding which has been shown to be reasonably specific
for HCC. This can be a useful addition to the toolbox
when looking at a lesion with non-specific enhancement
characteristics as intracellular lipid is very rare in a re-
generative or dysplastic nodules [51] (Fig. 3).
In the event of uncertainty a consensus opinion is
reached from the available liver imaging specialists in
the department. Lesions with focal hepatic arterial en-
hancement, but without washout, capsule enhance-
ment, or abnormal increased T2 signal, are considered
dysplastic nodules (if clearly a defined nodule) or non-
specific hypervascular lesions (if nonmarginated and
subcapsular).
We review prior imaging and clinical information for
all patients. An understanding of the treatment options
for HCC under the current guidelines is essential. We
structure the conclusions of our reports so that the
multidisciplinary liver group can make informed deci-
sions in the context of the options available.
Reports indicate the size (largest axial or coronal sec-
tion diameter), number, and location of HCC lesions.
The Couinaud classification is used for anatomic refer-
ence [52]. Although the system was designed for surgical
planning it is universally accepted, simple, and more
concise than the descriptive terms for the segmental
anatomy. The coronal measurement is frequently omit-
ted in reports but is important because it affects the
treatment stratification, both for transplant evaluation
and for determination of the type of locoregional therapy
to be used.
Fig. 2 67 year old male with alchohol liver disease and cirrhosis.
Venous phase MRI with gadolinium demonstrates an HCC nodule
at the dome of the liver with capsular enhancement
Table 2 MRI major and ancillary features for the diagnosis of HCC
HCC: major feature s HCC: ancillary features
Arterial phase enhancement T2-w hyperintensity
Delayed phase “washout” Restriction of diffusion
Threshold growth Intra-lesional fat
Delayed enhancing capsule
Fig. 3 71 year old male with hepatitis C cirrhosis. Signal drop out on
opposed phase imaging (b) in comparison with in phase imaging
(a). The findings represent intracellular lipid in an HCC tumour
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We number the tumors from 1 to 4. If there are more
than 4 lesions then we determine whether there is unilo-
bar or bilobar disease and describe how many lesions
there are in each lobe, again numbering them so that
they can be easily detected. We believe in the import-
ance of providing series and image numbers for each
lesion up to 4 lesions so that if the reporting radiologist
is not present at the multidisciplinary meeting, or if sur-
geons or liver specialists are looking at the images, they
can find the lesions quickly and not become confused by
other confounding imaging findings.
For each lesion the T1-weighted, T2-weighted, diffusion
weighted and contrast enhanced characteristics are always
described. If there are ancillary findings, for example sig-
nal dropout on opposed phase imaging in contrast with in
phase imaging, then we add those as well. Although we do
not strictly apply a LIRADS (Liver Imaging Reporting and
Data System) number to each lesion, we report findings in
the context of the LIRADS criteria as these are the current
most comprehensive guidelines used to stratify the risk
malignancy in the context of cirrhosis and HCC [53]. LIR-
ADS is a useful system to use when there is not close
communication in a multidisciplinary setting. It is easily
accessible online and the system is helpful for those cases
where there is some uncertainty.
For specific examples which are not clearly covered by
guidelines, our experiences are that small nodule-like ar-
terial enhancing lesions which do not show associated
washout, but which increase in conspicuity over time,
merit close attention on follow up imaging as these often
develop ancillary features of washout, pseudocapsule or
restricted diffusion over time. Small foci of restricted dif-
fusion or high T2-weighted signal with arterial enhance-
ment often turn out to be HCC, whereas small foci or
restricted diffusion without arterial enhancement, and
without other ancillary features, are very common, and
are almost always not related to cancer.
A review for extrahepatic disease is essential as meta-
static disease changes all of the treatment pathways. The
lungs should be imaged once HCC is diagnosed. Meta-
static disease is seen in multiple locations but portal
lymph nodes, peritoneum, adrenal glands and bones are
the more frequent locations.
Selection and staging
Once a patient is diagnosed with HCC, a multidisciplin-
ary approach is adopted to determine optimal therapy
and further management. Our group includes transplant
surgeons, hepatologists, oncologists, radiation oncologists,
and cross-sectional and interventional radiologistsWe pre-
pare the cases for presentation each week.
Although several staging schema have been developed,
none have been universally adopted. A few main factors
have been identified as influential in the prognosis of
patients with HCC. These include liver function, tumor
size and number, tumor extent, including vascular inva-
sion and extrahepatic spread, evidence of portal hyperten-
sion, and clinical performance status. Tumor proximity to
large vessels and main bile ducts can also be pertinent
with regard to ablative therapies, and is worth mentioning
if these treatments are likely to be considered.
CT and MRI are useful in identifying tumor extent
and extrahepatic spread. They also provide secondary
evidence of portal hypertension, including the presence
of splenomegaly and portosystemic collaterals. Imaging
of the chest is also recommended as part of the initial
work up, given that lung and bone are common sites
for HCC metastasis. A bone scan can also be performed
if there is a suspicion for osseous metastasis, or if the
patient is being considered for liver transplantation.
The Barcelona Clinic Liver Cancer (BCLC) system links
the staging of HCC in patients with cirrhosis with treat-
ment options, making it the most commonly adopted
staging system [5, 6].
The BCLC system identifies those patients with early
stage HCC who may benefit from curative therapies
(stage 0 and A), those at intermediate (stage B) or ad-
vanced (stage C) stages who may benefit from palliative
treatments, and those who are most suitable for best
supportive care (stage D). Curative treatment options,
including transplantation, resection, and ablation for pa-
tients with early stage disease depends on local factors,
patient specific issues, and patient preference. Palliative,
non-curative treatment options include transcatheter ar-
terial chemoembolization (TACE) for stage B disease,
radioembolisation, and sorafenib for advanced stage C dis-
ease. TACE is also increasingly used as a “bridge” to trans-
plant, and in some cases to downstage patients so that
they can become candidates for a transplant list [54, 55].
In equivocal cases where the diagnosis of HCC is un-
certain in small lesions, a reasonable approach is to wait
3 months and image again [56, 57].
Post therapy imaging
Because many patients with HCC do not meet criteria
for transplantation or surgery, a large proportion of pa-
tients receive locoregional therapy or systemic therapy
and therefore require post-therapy imaging to evaluate
for initial response and recurrent disease. No established
guidelines for ideal surveillance time intervals exist. Re-
currence is 6.5 times more likely to occur in the first
year after therapy than in the second year, so most
guidelines suggest 3 monthly interval imaging in the first
year after treatment [58]. We follow up with imaging at
3 month intervals for one year followed by 6 month in-
tervals for 2 years, and then we return to ultrasound
screening. It is important to use the same modality for
each follow up as comparison between CT and MRI can
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be challenging. We generally use MRI for follow up as
the imaging findings can be more difficult to interpret
following treatment and the subtraction images can be
really useful (Fig. 4).
Several systems have been developed to objectively
evaluate the response of HCC to locoregional therapy.
Some of these are based on tumor size, such as the WHO
(World Health Organisation) and RECIST (Response
Evaluation Criteria in Solid Tumours) criteria [59, 60],
while others, such as EASL, AASLD, and mRECIST, are
based on the assessment of residual enhancing HCC
[61, 62]. mRECIST, or modified RECIST, therefore does
not evaluate tumour bulk itself, as does RECIST, as this
may not change after treatment, or may even increase, but
assesses the volume of residual functional tumour or ar-
terial enhancing tissue [63]. Studies have shown that the
mRECIST and EASL enhancement-based protocols cor-
relate more accurately with residual disease burden and
with survival after therapy than the size-based protocols
for patients treated with ablation, radioembolization and
TACE [63–67]. At our multidisciplinary meetings we use
a combination of mRECIST and EASL criteria to quantify
residual or recurrent tumour, along with informed discus-
sion from the team members (Table 3).
Prior to reporting we make sure we have established
the procedures performed or therapies used, as lack of
awareness of these can lead to embarrassing errors in
reporting. Regardless of the therapy performed, treated
tumor should demonstrate an absence of enhancement.
A thin rim of enhancement can be seen as a normal
finding after ablation and TACE due to adjacent
hyperemia and fibrosis (Fig. 5). However, residual or
Fig. 4 66 year old female with hepatitis C cirrhosis post microwave
ablation of HCC Precontrast image post microwave ablation (a)
show a cavity with intrinsic high signal on T1 weighted imaging. A
subtraction image (b) removes the high signal resulting in no
evidence of enhancement
Table 3 Summary of mRECIST and EASL responses
mRECIST EASL
Complete Response Disappearance of any intratumoral arterial enhancement
in all target lesions (up to 2 measurable liver lesions)
Disappearance of any intratumoral arterial enhancement
in all measurable arterial enhancing liver lesions
Partial Response Decrease >30% in the sum of longest diameters of viable target lesions Decrease >50% in the sum of the product of
bidimensional diameters of viable target lesions
Progressive Disease Increase >20% in the sum of longest diameters of viable target lesions Increase >25% in the sum of the diameters of
viable target lesions
Stable Disease None of the above None of the above
Fig. 5 63 year old male with cirrhosis and HCC treated with
microwave ablation. A thin rim of enhancement post ablation,
consistent with hyperemia adjacent to the ablation zone, is a normal
finding and does not represent recurrent tumour
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recurrent disease presents as thick or nodular peripheral
arterial enhancement [65, 68, 69] (Fig. 6). Post-ablation
changes are similar regardless of what type of ablation is
performed. The ablation zone should be larger than the
original tumor by between 5 and 10 mm. If it is not,
then careful attention to subtle enhancing lesions is
needed. Ablation zones can decrease in size with time.
An ablation zone can demonstrate high signal intensity
on pre-contrast T1-weighted images as a result of coagu-
lative necrosis, making evaluation for arterial enhance-
ment difficult in the absence of subtraction imaging.
Subtractions should therefore be routinely included within
the MRI protocol [22].
Conclusions
The accepted modality for hepatocellular carcinoma
screening is ultrasound. Once HCC is suspected then
CT or MRI may be used to confirm the diagnosis and
establish the tumor burden for staging purposes. The
BCLC classification system is the most frequently used
for treatment planning. However, multidisciplinary meet-
ing and planning is essential to ensure that the correct
pathways are adopted within the context of each institu-
tion. Following surgical, locoregional, chemotherapeutic
or radiotherapeutic treatment, follow up imaging and
regular multidisciplinary discussion is adopted.
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